99% High Purity Mazdutide

Name:  Lynn
Wechat：  15914422644

Tel：+86  15914422644

Whatsapp: +852 6252 8290

Email：    guangsheng 5   @zgguangsheng.com

I. Basic Information & Structural Design

1. Core Structure: A modified 37-amino-acid peptide engineered for enhanced stability and prolonged half-life. Key modifications include substitution of the second amino acid with alpha-aminoisobutyric acid (Aib) to resist DPP-4 degradation, and conjugation of a C20 fatty diacid moiety to lysine at position 20 via a hydrophilic linker, promoting serum albumin binding.
2. Key Parameters: Molecular formula C₂₀₉H₃₃₁N₅₅O₅₈; molecular weight ~4711 Da; CAS No. 2427649-22-4, PubChem CID 162133334.
3. Dosage Form & Storage: Sterile, lyophilized powder for subcutaneous injection after reconstitution with normal saline. Store at 2–8°C; avoid freezing or exposure to light. Long-acting formulation enables once-weekly administration.

II. Mechanism of Action

1. GLP-1 Receptor Activation: Slows gastric emptying, enhances satiety, reduces food intake, stimulates glucose-dependent insulin secretion, and suppresses inappropriately elevated glucagon release, lowering blood glucose and promoting weight loss.
2. Glucagon Receptor Activation: Increases energy expenditure (thermogenesis), improves hepatic fat metabolism, and reduces visceral adipose tissue, complementing GLP-1-mediated weight loss with enhanced fat-burning effects.
3. Metabolic Benefits: Improves insulin sensitivity, reduces waist circumference, blood pressure, triglycerides, and liver fat content, addressing multiple cardiometabolic risk factors.

III. Clinical Applications & Key Data

1. Chronic Weight Management (Approved Indication)

• Indications: Adults with BMI ≥28 kg/m² (obesity) or BMI ≥24 kg/m² (overweight) plus at least one weight-related comorbidity (e.g., hypertension, dyslipidemia, T2D).
• Efficacy: Phase 3 trials (GLORY-1/2) showed dose-dependent weight reduction: 4 mg/week (-10.5% body weight at 24 weeks), 6 mg/week (-12.6% at 24 weeks). Significant reductions in visceral fat, waist circumference, and blood pressure were also observed.

2. Type 2 Diabetes (Investigational)

• Efficacy: Phase 3 DREAMS-2 trial demonstrated superior HbA1c reduction vs. dulaglutide (1.5 mg): 4 mg (-1.6%) and 6 mg (-1.8%) at 28 weeks, with additional benefits in weight loss, lipid profiles, and liver enzymes.
• NDA Status: NMPA accepted an NDA for T2D indication in 2025, pending approval.

IV. Dosage, Administration & Safety

1. Recommended Dosage:
   • Weight Management: Start at 2 mg weekly for 4 weeks, then escalate to 4 mg/week; 6 mg/week may be used for additional weight loss if tolerated.
   • T2D: 4 mg or 6 mg weekly, adjusted based on glycemic control and tolerability.
   
   
2. Administration: Subcutaneous injection in the abdomen, thigh, or upper arm, once weekly (any day, consistent timing).
3. Adverse Reactions: Mostly mild-to-moderate gastrointestinal events (nausea, diarrhea, vomiting, constipation) occurring early and resolving with continued use. Rare side effects include hypoglycemia (more common with concurrent insulin/sulfonylureas), injection-site reactions, and transient elevated liver enzymes.
4. Contraindications & Precautions: Contraindicated in hypersensitivity to mazdutide or excipients, history of medullary thyroid carcinoma (MTC), or multiple endocrine neoplasia syndrome type 2 (MEN 2). Use caution in patients with pancreatic disease, renal impairment, or severe gastrointestinal disorders. Monitor HbA1c, lipid profiles, and liver function regularly.